Trial Site Detail
Drug: |
Dasatinib (BMS-354825) +
Bevacizumab |
|||
|---|---|---|---|---|
Trial: |
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
|
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Ongoing, but not recruiting |
|||
Warren Grant Magnuson Clinical Center9000 Rockville Pike
|
Principal Investigator: |
Christina M Annunziata, M.D. |
|---|---|
Contact: |
Christina M Annunziata, M.D. 301-402-7189 ca180n@nih.gov Nicole D. Houston, R.N. (301) 443-6431 houstonnd@mail.nih.gov |
Activation Status of this Site: |
Active |
Notes about this Site: |
|
Warren Grant Magnuson Clinical Center Website: |
http://bethesdatrials.cancer.gov/clinical-research/index.aspx |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.